Latest news with #HumanLongevity
Yahoo
3 days ago
- Business
- Yahoo
Tony Robbins and Peter Diamandis' longevity company Fountain Life raises $18M
Eight years ago, orthopedic surgeon Dr. William Kapp attended a medical conference that changed his professional life. He had gone from a private practice doctor to co-founding a company that built critical care hospitals to then selling that company. It gave him an interest for both sides of healthcare: the medicine and business sides, he told TechCrunch. So he went to the annual conference hosted by famed physician-scientist Dr. Daniel Kraft to learn about new tech that could improve results while lowering costs. Dr. Peter Diamandis, founder and chairman of the XPRIZE Foundation, was on stage that year with Dr. Bob Hariri, a stem-cell pioneer and co-founder of several health techs like genomics company, Human Longevity, Kapp said. They discussed genomics, microbiomics, and new tech that wasn't part of mainstream medicine. Inspired, Kapp went back to his home town of Naples, Florida, and 'started a thing called Longevity Performance Center. The idea was to do early detection and then optimization of people's health,' he said. In March 2020, Diamandis (pictured above) and his buddy Tony Robbins heard of Kapp's center and visited. They had a stem cell startup called Fountain Therapeutics. Conversation soon turned toward a merger, and by October that year, the two companies became Fountain Life. Kapp remained CEO with both Diamandis and Robbins as his co-founders and board members. Today his board also includes Hariri as an adviser; Todd Wanek, CEO of Ashley Furniture Industries, as an investor; and wealthy Indian business mogul B.K. Modi as an investor as well. Fountain Life tells TechCrunch exclusively that it just raised an $18 million series B, led by EOS Ventures, with participation from most of the existing members of the board. Fountain previously raised an $80 million Series A and has raised about $108 million total, Kapp said. Longevity as a subject of serious study by the medical community is a new field. When Kapp (pictured below) first launched his center, 'We didn't know exactly what longevity meant,' he said. But over the last four or five years, much more research has been done. The first principle of longevity, he said, is 'don't die of anything stupid.' Therefore, Fountain Life's centers, of which there are four today, have a heavy focus on prevention screening, looking for illnesses and chronic conditions at their earliest stages when they tend to be asymptomatic. Blood tests and body scans gather data on over 100 biomarkers from liver fat to 'microbiome concentrations,' he said. The second principal is optimization, meaning improving those markers with scientifically validated treatments, he said. And the third principal is 'using the latest regenerative therapies under FDA trials,' to treat illness or achieve optimization. Screening tests may discover, for example, small intestinal bacterial overgrowth (SIBO), which, left untreated, may lead to certain cancers, he said. The solution, if caught early, is to restore microbiome balance with specific, prescribed microbiotics. For Fountain's members, testing is repeated every quarter or so, and patients can track results and ask questions of an AI-powered app called Zori. But it's pricey, Kapp admitted. A full subscription costs $30,000 a year, and $10,000 will cover just the testing process and AI, but not ongoing tests and medical support. Still, Kapp remembers two stories that told him this work was on the right track. The wife of a Robbins fan bought a membership for her husband, and the tests caught early-stage, asymptomatic kidney cancer. The husband is now cancer-free. When global hotelier Sam Nazarian was exploring a partnership with Fountain to put longevity centers in luxury hotels, Nazarian did Fountain's tests and found a brain aneurysm. They successfully treated it, Nazarian has publicly said. Kapp says the new funding will allow the company to open more centers. In addition to Naples; Westchester, New York; Orlando; and Dallas, a center in Houston will open in December. Centers in Los Angeles and Miami are planned for Q2 of 2026. He hopes to solve the affordability issue by working on 'clinic development' where Fountain trains medical facilities on its methodologies. Kapp says that as the tech and expertise become more widely available, this will drive down costs for access. Fountain is not the only doctor-driven longevity testing startup. Famed functional health doctor Mark Hyman has a company called Function Health. It offers a package of about 160 blood tests, with follow-up tests every three to six months, for a $500/year membership (with additional fees for additional blood tests). Its platform similarly analyzes and tracks test results, although it doesn't do full body scans or offer direct access to physicians.
TechCrunch
3 days ago
- Business
- TechCrunch
Tony Robbins' and Peter Diamandis' longevity company Fountain Life raises $18M
Eight years ago, orthopedic surgeon Dr. William Kapp attended a medical conference that changed his professional life. He had gone from a private practice doctor to co-founding a company that built critical care hospitals to then selling that company. It gave him an interest for both sides of healthcare: the medicine and business sides, he told TechCrunch. So he went to the annual conference hosted by famed physician-scientist Dr. Daniel Kraft to learn about new tech that could improve results while lowering costs. Dr. Peter Diamandis, founder and chairman of the XPRIZE Foundation, was on stage that year with Dr. Bob Hariri, a stem-cell pioneer and co-founder of several health techs like genomics company, Human Longevity, Kapp said. They discussed genomics, microbiomics, and new tech that wasn't part of mainstream medicine. Inspired, Kapp went back to his home town of Naples, Florida, and 'started a thing called Longevity Performance Center. The idea was to do early detection and then optimization of people's health,' he said. In March 2020, Diamandis (pictured above) and his buddy Tony Robbins heard of Kapp's center and visited. They had a stem cell startup called Fountain Therapeutics. Conversation soon turned toward a merger, and by October that year, the two companies became Fountain Life. Kapp remained CEO with both Diamandis and Robbins as his co-founders and board members. Today his board also includes Hariri as an adviser; Todd Wanek, CEO of Ashley Furniture Industries, as an investor; and wealthy Indian business mogul B.K. Modi as an investor as well. Techcrunch event Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital, Elad Gil — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $600+ before prices rise. Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $675 before prices rise. San Francisco | REGISTER NOW Fountain Life tells TechCrunch exclusively that it just raised an $18 million series B, led by EOS Ventures, with participation from most of the existing members of the board. Fountain previously raised an $80 million Series A and has raised about $108 million total, Kapp said. Longevity as a subject of serious study by the medical community is a new field. When Kapp (pictured below) first launched his center, 'We didn't know exactly what longevity meant,' he said. But over the last four or five years, much more research has been done. The first principle of longevity, he said, is 'don't die of anything stupid.' Therefore, Fountain Life's centers, of which there are four today, have a heavy focus on prevention screening, looking for illnesses and chronic conditions at their earliest stages when they tend to be asymptomatic. Blood tests and body scans gather data on over 100 biomarkers from liver fat to 'microbiome concentrations,' he said. The second principal is optimization, meaning improving those markers with scientifically validated treatments, he said. And the third principal is 'using the latest regenerative therapies under FDA trials,' to treat illness or achieve optimization. Screening tests may discover, for example, small intestinal bacterial overgrowth (SIBO), which, left untreated, may lead to certain cancers, he said. The solution, if caught early, is to restore microbiome balance with specific, prescribed microbiotics. Dr. William Kapp Image Credits:Fountain Life For Fountain's members, testing is repeated every quarter or so, and patients can track results and ask questions of an AI-powered app called Zori. But it's pricey, Kapp admitted. A full subscription costs $30,000 a year, and $10,000 will cover just the testing process and AI, but not ongoing tests and medical support. Still, Kapp remembers two stories that told him this work was on the right track. The wife of a Robbins fan bought a membership for her husband, and the tests caught early-stage, asymptomatic kidney cancer. The husband is now cancer-free. When global hotelier Sam Nazarian was exploring a partnership with Fountain to put longevity centers in luxury hotels, Nazarian did Fountain's tests and found a brain aneurysm. They successfully treated it, Nazarian has publicly said. Kapp says the new funding will allow the company to open more centers. In addition to Naples; Westchester, New York; Orlando; and Dallas, a center in Houston will open in December. Centers in Los Angeles and Miami are planned for Q2 of 2026. He hopes to solve the affordability issue by working on 'clinic development' where Fountain trains medical facilities on its methodologies. Kapp says that as the tech and expertise become more widely available, this will drive down costs for access. Fountain is not the only doctor-driven longevity testing startup. Famed functional health doctor Mark Hyman has a company called Function Health. It offers a package of about 160 blood tests, with follow-up tests every three to six months, for a $500/year membership (with additional fees for additional blood tests). Its platform similarly analyzes and tracks test results, although it doesn't do full body scans or offer direct access to physicians.
Yahoo
17-07-2025
- Health
- Yahoo
Human Longevity, Inc. Expands $1 Million Cancer Prevention Pledge to Safeguard Against Late-Stage Ovarian Cancer
New pledge underscores confidence in early detection, supported by the Avantect® Liquid Biopsy and HLI's Executive Health Program SOUTH SAN FRANCISCO, Calif., July 17, 2025 /PRNewswire/ -- Human Longevity, Inc. (HLI), a global leader in precision medicine and proactive healthcare, today announced the expansion of its $1 million cancer prevention pledge — now focused on late-stage ovarian cancer. Reflecting HLI's unwavering belief in early detection and the power of precision diagnostics, this bold initiative will offer up to $1 million in treatment and clinical support for any qualified member diagnosed with late-stage ovarian cancer while actively participating in HLI's Executive Health Program or affiliated 100+ Longevity Programs. Pioneering Early Detection with Avantect® Liquid BiopsyThrough its Executive Health Program, Human Longevity has screened over 10,000 members using a comprehensive, AI-driven platform that integrates genomics, imaging, and biomarkers. This ovarian cancer prevention initiative will now incorporate the Avantect® Ovarian Cancer Liquid Biopsy — the first clinically validated blood test to detect early-stage ovarian cancer with high negative predictive value (NPV). By identifying tumor-derived cell-free DNA signals, the Avantect® test enhances HLI's multi-modal detection strategy. This precision strategy includes: Whole genome sequencing, including BRCA1/2 and other hereditary cancer-related genes Whole-body MRI with dedicated pelvic imaging Avantect® Ovarian Cancer Liquid Biopsy Multi-cancer early detection (MCED) blood tests Continuous symptom and biomarker monitoring This integrated approach—offered exclusively through HLI's Executive Health Program—allows Human Longevity to detect ovarian cancer earlier and with greater confidence, empowering women with better outcomes. How the Initiative WorksEligible participants must be continuously enrolled in the Executive Health Program or 100+ Longevity Programs, and must complete annual ovarian cancer-specific screenings, including the Avantect® liquid biopsy, as part of their clinical protocol. If a participating member is diagnosed with late-stage ovarian cancer during active membership, HLI will provide up to $1 million in treatment support, clinical navigation, and consultation with top gynecologic oncology experts. "Prevention is the future of medicine," said Dr. Wei-Wu He, Executive Chairman of Human Longevity, Inc. "With the Avantect® liquid biopsy in addition to our Executive Health Program, we are further strengthening our ability to catch cancer before it's too late. And in the rare case we miss something, our pledge ensures our members receive the best care in the world." Leading the Future of Women's HealthOvarian cancer is among the most lethal gynecologic cancers due to its late-stage diagnoses. By combining cutting-edge tools like Avantect®, advanced imaging, and AI-enabled analytics within the Executive Health Program, Human Longevity is redefining what's possible in women's health and cancer prevention. This pledge is more than a financial commitment—it's a call to action for precision prevention. It reflects HLI's mission to radically shift healthcare from reactive to proactive, ensuring its members benefit from the most advanced tools available. About Human Longevity, Longevity, Inc. is a biotechnology company at the forefront of integrating genomics, AI, and multimodal diagnostics to extend human healthspan. Through its flagship Executive Health Program and 100+ Longevity Programs, HLI delivers comprehensive, data-driven evaluations aimed at identifying and preventing disease long before symptoms arise. To learn more or how to enroll, visit or Media Contact:media@ View original content to download multimedia: SOURCE Human Longevity, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-06-2025
- Business
- Yahoo
/C O R R E C T I O N -- Human Longevity, Inc./
In the news release, Human Longevity, Inc. Expands Pancreatic Cancer Prevention Commitment with $1 Million Pledge for Qualified Members, issued 17-Jun-2025 by Human Longevity, Inc. over PR Newswire, we are advised by the company that the media contact information should be added to the public distribution. The complete, corrected release follows: SOUTH SAN FRANCISCO, Calif., June 17, 2025 /PRNewswire/ -- Human Longevity, Inc. (HLI), a global leader in precision medicine and proactive health, today announced an expansion of its $1 million pledge initiative—this time targeting late-stage pancreatic cancer. Building on the success of its recent prostate cancer commitment, HLI is advancing its mission to detect cancer earlier and improve outcomes for its members by offering financial and clinical support for those members diagnosed with late-stage pancreatic cancer while enrolled in its Executive Health and 100+ Longevity programs. Driving Innovation in Early Detection Through its Executive Health Program and 100+ Longevity Programs, Human Longevity has delivered care to over 10,000 members using a comprehensive platform that integrates whole genome sequencing, advanced imaging, and multiplex blood biomarker tracking. These efforts have enabled the development of what HLI believes to be one of the most advanced early detection algorithms for pancreatic cancer available today, including a new proprietary DNA-based pancreatic cancer screening test. In most cases, our multi-modal screening approach helps detect cancer at a stage when it is curable. But in the rare event that a member is diagnosed at a late stage, our $1 million pledge ensures they receive the most advanced care available—without the burden of financial barriers. How the $1 Million Pledge Works Eligible individuals must be active pledge participants in HLI's Executive Health Program or affiliated Longevity Programs for pancreatic cancer early screening. These programs include: Whole genome sequencing Whole-body MRI, with dedicated pancreatic imaging Long-term blood biomarker analysis A DNA-based pancreatic cancer screening blood test Qualified members diagnosed with late-stage pancreatic cancer while under HLI's care will receive up to $1 million toward treatment, care coordination, and access to a network of top-tier oncology experts from leading medical institutions. Transforming the Future of Pancreatic Cancer Care Pancreatic cancer is one of the deadliest forms of cancer due to its lack of early symptoms and late detection. Human Longevity's initiative aims to shift this paradigm by detecting disease earlier—when it is most treatable. The pledge not only offers support to individuals but also accelerates advancements in cancer screening technology through continuous real-world data integration and machine learning. About Human Longevity, Inc. Human Longevity, Inc. is a pioneering biotechnology company at the forefront of genomics, AI, and advanced medical technologies to extend healthspan and revolutionize preventative care. By leveraging vast genomic data, metabolomics, advanced imaging, and AI-driven diagnostics, Human Longevity is transforming healthcare from disease management to proactive prevention through its Executive Health and other Longevity Programs. The company remains committed to advancing medical research, improving patient outcomes, and unlocking the full potential of genomics to address the world's most pressing health challenges. Media Contactmedia@ View original content to download multimedia: SOURCE Human Longevity, Inc.
